SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549
                               ------------------

                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER

                    Pursuant to Rule 13a-16 or 15d-16 of the
                         Securities Exchange Act of 1934


                         For the month of: November 2002

                             World Heart Corporation
                       -----------------------------------
               (Exact name of registrant as specified in charter)

                                       N/A
                      -----------------------------------
                 (Translation of registrant's name into English)

                                     Ontario
                      -----------------------------------
                         (Jurisdiction of organization)

                     1 Laser Street, Ottawa, Ontario K2E 7V1
                      -----------------------------------
                    (Address of principal executive offices)

                  Registrant's telephone number: (613) 226-4278



Indicate by check mark whether the registrant  files or will file annual reports
under cover of Form 20-F or Form 40-F.

                           Form 20-F  X       Form 40-F
                                     ---                 ---


Indicate by check mark whether the  registrant  by  furnishing  the  information
contained  in this  Form is  also  thereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes              No   X
                                 ---              ---

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):82-
                                  -----------------------.







<PAGE>



This Form 6-K consists of the following:

1.   Press  release  of  World  Heart  Corporation,  dated  November  11,  2002,
     announcing its third quarter results for the 2002 fiscal year.




<PAGE>


For Immediate Release

                        WORLDHEART ANNOUNCES Q3 RESULTS:
                        -------------------------------
                    Revenues Up, Expenses and Cash Usage Down


OTTAWA, Ont. - November 11, 2002 (OTCBB: WHRTF, TSX: WHT) - World Heart
Corporation (WorldHeart) today released its unaudited consolidated financial
results for the third quarter, and nine months ended September 30, 2002.
Revenues for the nine months were up 50%, and expenses were down 27%, compared
with the same nine months last year. All revenues in both periods related
exclusively to sales of Novacor(R) LVAS and related hardware. Unit sales of
Novacor(R) LVAS were 32 in the third quarter, up 39% from the second quarter
this year.

Sixteen new clinics began using Novacor(R) LVAS so far this year in the United
States, Canada and Europe. These centers have begun Novacor(R) LVAS implants,
and together with growing use in existing centers, are expected to contribute
significant growth in demand for Novacor(R) LVAS next year. European sales were
reduced in the first half of this year, pending release of the company's
enhanced ePTFE inflow conduit. The ePTFE conduit was released in Europe at the
end of the second quarter, resulting in increased European sales for the third
quarter. Clinical results of implants using the ePTFE conduit have been
extremely positive, contributing to continued growth in sales entering the
fourth quarter.

"Premarket Approval (PMA) Supplement to approve the use of the ePTFE conduit
with the Novacor(R) LVAS has been submitted in the U.S.," said Rod Bryden,
President and CEO of WorldHeart.

"We expect sales for Novacor(R) LVAS to approximately double over the next five
quarters, reflecting expansion in active implant centers and anticipated
approval of the ePTFE conduit in the U.S. and eventually in Canada," Mr. Bryden
said.

Revenues for the first nine months of 2002 were $8,191,284, compared with
$5,458,380 for the same period last year. Gross margin for the same period was
($385,916), compared with ($1,113,615) a year ago. Net loss for the nine months
was $37,366,333, or $2.11 per share, compared with $45,372,399, or $3.00 per
share last year. Total cash applied to operations during the first nine months
of this year was $19,884,909, compared with $32,614,456 a year ago.

For the three months ended September 30, 2002, revenues were $3,049,036,
compared with $2,636,728 a year ago, providing gross margin in the second
quarter this year of ($127,340), compared with $487,289 last year. Net loss for
the third quarter was $14,363,490, or $0.80 per share, compared with
$16,968,842, or $1.12 per share a year ago. The operating loss was $9,414,680
for the third quarter, compared with $13,351,135 for the same period last year.
Total cash used during the third quarter this year was $3,766,916, compared with
$11,223,833 for the same period last year. Cash and short-term investments on
hand at September 30, 2002 was $2,341,550, compared with $13,706,770 at the same
date a year ago. Cash balances at September 30, 2002 do not include $3,500,000
remaining under an agreement with Technology Partnership Canada (TPC), which is
expected to be received during the fourth quarter.

Revenue growth through 2003 is expected to accelerate as we add sales
representatives in the U.S., and expand the sales and marketing activities with
Edwards Lifesciences LLC in Europe and Japan," Rod Bryden said. "This revenue
growth, and achieving by the end of the fourth quarter the full benefits of
expense reduction actions taken in the second quarter, are expected to continue
to reduce operating losses and cash requirements. However, additional capital
will be required early in 2003 to

<PAGE>

fund the continued operation of the business. Actions are in process to bring in
the required capital," he said.

"On Tuesday, November 6, 2002, it was announced that the US Food and Drug
Administration (FDA) had approved the use of a pulsatile implantable LVAD (left
ventricular assist device) for "Destination Therapy" for end-stage heart failure
patients who are not candidates for transplantation. This is a positive and
significant step toward expanding the eligible patient population and bringing
LVAD technology to wide acceptance as a therapy for end-stage heart failure.
WorldHeart submitted a PMA Supplement to the FDA for approval of the Novacor(R)
LVAS for this indication on August 15, 2002. While expedited review was granted
by the FDA, the Agency declined to file the application until resolution of an
issue respecting the data submitted in support of the application. The company
is pursuing the review process provided by the FDA to seek to resolve this
issue. A final conclusion on filing may not be reached until early next year,"
Mr. Bryden said.

Worldwide, 1400 patients have received the Novacor(R) LVAS. More than 90% of
these patients were implanted while awaiting heart transplantation. No deaths
have been attributed to device failure, an unmatched record. A total of 296
recipients have been supported by their device for more than 6 months. Within
that total, 116 recipients have been supported for over one year, 26 recipients
for over two years, 9 recipients for over three years, and 3 recipients have
been supported for over four years - statistics unmatched by any other implanted
cardiac assist device on the market.

Novacor(R) LVAS is already approved in Europe without restriction for use by
heart-failure patients; and in the U.S. and Canada as a bridge to heart
transplantation. It is the only LVAD approved for long-term use in Japan.

As clinical focus shifts to long-term use of LVADs, the unmatched record of
Novacor(R) LVAS for reliability, durability and predictability, is expected to
become an increasingly important factor in device selection. WorldHeart will
focus its production, marketing, sales and support capabilities on building
market share for Novacor(R) LVAS during the next four years. During that time,
the company will invest in bringing the next-generation HeartSaverVAD(TM) to
market.

"On August 21, 2002, WorldHeart announced that the HeartSaverVAD(TM) program
would be revised. Technologies developed by WorldHeart since 1996, in addition
to technologies licensed from the University of Ottawa Heart Institute, and
technologies included in the acquisition of Novacor(R) LVAS, provided the basis
for dramatic enhancements to HeartSaverVAD(TM). Planning for the
HeartSaverVAD(TM) development and trials program advanced during the third
quarter, to permit launching the development program in the fourth quarter. We
believe that this program will deliver to heart-failure patients an attractive
alternative to medical therapy or other alternatives for long-term support," Mr.
Bryden said.

Dr. Tofy Mussivand, Chief Scientific Officer of WorldHeart, described
HeartSaverVAD(TM) as a breakthrough in VAD design: "The next generation
HeartSaverVAD has advanced significantly since announcement of the revised
product development program on August 21, 2002. HeartSaverVAD(TM) will be
bearingless and magnetically actuated, contributing to its reliability and
durability. The enhanced HeartSaverVAD(TM) will be fully implantable, pulsatile
and remotely monitored and controlled. The design eliminates the volume
displacement chamber, and provides full pulsatility in a device that will be
less than half the size and weight of the Novacor(R) LVAS," Dr. Mussivand
stated.

"At less than 350 ml in volume, HeartSaverVAD(TM) will comfortably support most
teenage and adult patients. Thoracic or abdominal placement will be the choice
of the patient and clinician, and patient comfort and convenience will
contribute to a near-normal lifestyle. We believe that achieving these

<PAGE>

results, while preserving the natural pulsing blood flow to match normal body
demands, will make HeartSaverVAD(TM) attractive to heart-failure patients," Dr.
Mussivand said.

Mr. Bryden concluded that: "Novacor(R) LVAS provides WorldHeart with the most
reliable device of the current generation to support heart-failure patients.
HeartSaverVAD(TM) promises to be the breakthrough product of the
next-generation, coming to market in four to five years."

About the Novacor(R) LVAS
WorldHeart's Novacor(R) LVAS is an electromagnetically driven pump that provides
circulatory support by taking over part or all of the workload of the left
ventricle. Novacor(R) LVAS is already approved in Europe without restrictions
for use by heart failure patients; and in the United States and Canada as a
bridge to heart transplantation. It is approved for use in Japan by cardiac
patients at risk of imminent death from non-reversible left ventricular failure
for which there is no alternative but a heart transplant.

About WorldHeart
World Heart Corporation, a global medical device company based in Ottawa,
Ontario and Oakland, California, is currently focused on the development and
commercialization of pulsatile ventricular assist devices. Its Novacor(R) LVAS
(Left Ventricular Assist System) is well established in the marketplace and its
next generation technology, HeartSaverVAD(TM), is a fully implantable assist
device intended for long-term support of patients with end-stage heart failure.

Any forward-looking statements in this release are made pursuant to the safe
harbour provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that all forward-looking statements involve risk and
uncertainties, including without limitation, risks in gaining access to required
capital, in product development and market acceptance of and demand for the
Corporation's products, risks of downturns in economic conditions generally, and
in the medical devices markets, risks associated with costs and delays posed by
government regulation, limitations on third party reimbursement, inability to
protect proprietary technology, potential product liability and other risks
detailed in the Corporation's filings with the U.S. Securities and Exchange
Commission. All financial figures are prepared in accordance with Canadian
generally accepted accounting principles (GAAP) and are expressed in Canadian
dollars


For more information, please contact:
-------------------------------------
Michelle Banning
Manager, Corporate Communications
(613) 226-4278, ext: 2995 or
(510) 563-4995
communications@worldheart.com

<PAGE>

World Heart Corporation
Summary Consolidated Statement of Loss
Amounts in thousands (except per share data), Canadian Dollars
<TABLE>
<S>                                                         <C>                 <C>            <C>            <C>

-------------------------------------------------------------------------------------------------------------------------
                                                             Three months ended                 Nine months ended
                                                          September 30,    September 30,    September 30,   September 30,
                                                                   2002             2001             2002            2001
-------------------------------------------------------------------------------------------------------------------------
                                                            (unaudited)      (unaudited)      (unaudited)     (unaudited)

Revenue                                                     $     3,049     $      2,636      $     8,191     $     5,458
Cost of goods sold                                               (3,176)          (2,149)          (8,577)         (6,572)
                                                            --------------------------------------------------------------
Gross margin                                                       (127)             487             (386)         (1,114)
                                                            --------------------------------------------------------------
Expenses
  Selling, general and administrative                            (2,509)          (2,873)          (7,798)         (7,721)
  Research and development                                       (4,947)          (7,232)         (18,232)        (24,083)
  Amortization of intangibles                                    (1,831)          (3,733)          (5,492)        (11,199)
                                                            --------------------------------------------------------------
                                                                 (9,287)         (13,838)         (31,522)        (43,003)
                                                            --------------------------------------------------------------

Loss before the undernoted                                       (9,414)         (13,351)         (31,908)        (44,117)

Other income (expenses)                                          (4,949)          (3,699)          (5,458)         (6,243)
Recovery of future income taxes                                       -               81                -           4,988
                                                            --------------------------------------------------------------

Net loss for the period                                     $   (14,363)    $    (16,969)     $   (37,366)   $    (45,372)
                                                            --------------------------------------------------------------
Weighted average number of common  shares                    17,970,127       15,099,392       17,715,105      15,111,393
                                                            --------------------------------------------------------------
Basic and diluted loss per common share                     $     (0.80)    $      (1.12)     $     (2.11)   $      (3.00)
--------------------------------------------------------------------------------------------------------------------------
</TABLE>


World Heart Corporation
Summary Consolidated Statement of Cash Flows
Amounts in thousands, Canadian dollars
<TABLE>
<S>                                                           <C>           <C>                <C>            <C>
--------------------------------------------------------------------------------------------------------------------------
                                                             Three months ended                 Nine months ended
                                                          September 30,    September 30,    September 30,   September 30,
                                                                   2002             2001             2002            2001
--------------------------------------------------------------------------------------------------------------------------
                                                            (unaudited)      (unaudited)      (unaudited)     (unaudited)

CASH FLOWS FROM (USED IN)

Operating activities                                        $   (2,336)      $   (9,613)       $ (17,966)    $   (29,255)
Investing activities                                            (1,344)            (286)           5,108          20,354
Financing activities                                               (41)          (1,262)            (197)         (1,341)
Effect of exchange rate changes on cash
     And cash equivalents                                          (45)             (63)              52            (176)
                                                              ------------------------------------------------------------
Increase / (decrease) in cash and cash
     equivalents for the period                                 (3,766)         (11,224)         (13,003)        (10,418)

Cash and cash equivalents beginning of the period                6,108           24,431           15,345          23,625
                                                              ------------------------------------------------------------
Cash and cash equivalents end of the period                 $    2,342       $   13,207       $    2,342     $    13,207
--------------------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

World Heart Corporation
Summary Consolidated Balance Sheet
Amounts in thousands, Canadian Dollars
<TABLE>
<S>                                                                                            <C>            <C>

--------------------------------------------------------------------------------------------------------------------------
                                                                                            September 30,    December 31,
                                                                                                     2002            2001
--------------------------------------------------------------------------------------------------------------------------
                                                                                              (unaudited)
ASSETS
    Current assets                                                                              $  15,395        $ 37,854
    Cash pledged as collateral for lease                                                            1,190               -
    Capital assets                                                                                  4,561           5,294
    Goodwill and other intangible assets                                                           29,243          34,735
                                                                                      ------------------------------------
                                                                                                $  50,389        $ 77,883
                                                                                      ------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY
Liabilities
    Current liabilities                                                                         $  14,649        $ 11,656
    Preferred shares                                                                               71,204          65,685
    Capital lease obligation                                                                            -              64
                                                                                      ------------------------------------
                                                                                                   85,853          77,405
                                                                                      ------------------------------------
Shareholders' equity
    Common stock, special warrants, rights and contributed surplus                                131,518         130,094
    Accumulated deficit                                                                          (166,982)       (129,616)
                                                                                      ------------------------------------
                                                                                                  (35,464)            478
                                                                                      ------------------------------------
                                                                                                $  50,389       $  77,883
--------------------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                    World Heart Corporation


Date: November 12, 2002             By:/s/ Ian Malone
                                       -----------------------------------
                                       Name:   Ian Malone
                                       Title:  Vice President Finance and
                                               Chief Financial Officer